General

Showing 1121–1136 of 1897 results

Article: P.28 The IGF-1 receptor inhibitor picropodophyllin (PPP) potentiates the anti-myeloma effects of the BH3 mimetic ABT-737
€2.42 Add to cart
Article: P.29 Polyneuropathy as presenting symptom of a nodal marginal zone lymphoma with monoclonal IgA- ? gammopathy: a case report
€2.42 Add to cart
Article: P.29 The multifaceted GATA2 gene in inherited myeloid malignancies: about a Belgian family
€2.42 Add to cart
Article: P.30 Acute myeloid leukaemia infiltrating-T lymphocyte characterization
€2.42 Add to cart
Article: P.30 The relation between the abnormality of the P53 gene and the epidemiological and biological parameters
€2.42 Add to cart
Article: P.31 Study of the miRNome of childhood myelodysplastic syndrome
€2.42 Add to cart
Article: P.31 The relation between the abnormality of the P53 gene and the clinical and therapeutic parameters in chronic lymphoid leukemia
€2.42 Add to cart
Article: P.32 Microcytic anemia: a rare presentation of Waldenström Macroglobulinemia
€2.42 Add to cart
Article: P.32 The generation and activation of Myeloid-Derived Suppressor Cells in Multiple Myeloma
€2.42 Add to cart
Article: P.33 Hematological and molecular responses in a case of refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) treated by Lenalidomide
€2.42 Add to cart
Article: P.33 Myeloma cast nephropathy leading to early kidney allograft dysfunction: a case report
€2.42 Add to cart
Article: P.34 Multiple Myeloma in the era of novel agents: a single center experience
€2.42 Add to cart
Article: P.35 Fatal idiopathic hyperammonemia after induction chemotherapy for acute myeloid leukemia
€2.42 Add to cart
Article: P.35 Performance evaluation of two automated digital morphology systems, Cellavision and HemaCAM in comparison with classical microscopic analysis focusing on rare events counting and on the pre-classification efficiency of the automated systems
€2.42 Add to cart
Article: P.36 Management of fit older AML: major prognostic value of cytogenetic markers is confirmed whatever the age
€2.42 Add to cart
Article: P.36 Phase 2, open-label, multicenter study to evaluate the efficacy and safety of pemigatinib in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement (FIGHT-203)
€2.42 Add to cart

Article: P.28 The IGF-1 receptor inhibitor picropodophyllin (PPP) potentiates the anti-myeloma effects of the BH3 mimetic ABT-737

Article: P.29 Polyneuropathy as presenting symptom of a nodal marginal zone lymphoma with monoclonal IgA- ? gammopathy: a case report

Article: P.29 The multifaceted GATA2 gene in inherited myeloid malignancies: about a Belgian family

Article: P.30 Acute myeloid leukaemia infiltrating-T lymphocyte characterization

Article: P.30 The relation between the abnormality of the P53 gene and the epidemiological and biological parameters

Article: P.31 Study of the miRNome of childhood myelodysplastic syndrome

Article: P.31 The relation between the abnormality of the P53 gene and the clinical and therapeutic parameters in chronic lymphoid leukemia

Article: P.32 Microcytic anemia: a rare presentation of Waldenström Macroglobulinemia

Article: P.32 The generation and activation of Myeloid-Derived Suppressor Cells in Multiple Myeloma

Article: P.33 Hematological and molecular responses in a case of refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) treated by Lenalidomide

Article: P.33 Myeloma cast nephropathy leading to early kidney allograft dysfunction: a case report

Article: P.34 Multiple Myeloma in the era of novel agents: a single center experience

Article: P.35 Fatal idiopathic hyperammonemia after induction chemotherapy for acute myeloid leukemia

Article: P.35 Performance evaluation of two automated digital morphology systems, Cellavision and HemaCAM in comparison with classical microscopic analysis focusing on rare events counting and on the pre-classification efficiency of the automated systems

Article: P.36 Management of fit older AML: major prognostic value of cytogenetic markers is confirmed whatever the age

Article: P.36 Phase 2, open-label, multicenter study to evaluate the efficacy and safety of pemigatinib in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement (FIGHT-203)